<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow transplantation (BMT) is a therapeutic process used to treat a variety of <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>After BMT, the documentation of engrafting with the use of genetic markers is obligatory </plain></SENT>
<SENT sid="2" pm="."><plain>C-band polymorphism is an excellent genetic marker because it occurs with high frequency in <z:hpo ids='HP_0000001'>all</z:hpo> populations studied and shows a high stability in vitro and in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>We studied a total of 36 patients: 15 with myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> and 21 with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA), submitted to BMT </plain></SENT>
<SENT sid="4" pm="."><plain>The majority of the patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> granulocyte <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CGL</z:e>; 10/15, 67%) and with SAA (17/21, 81%) showed a frequency of host cells around 15% (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CGL</z:e>) and 8% (SAA) in the first period analyzed (day +30 post-BMT); with a decrease in the others (+90, +180 to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CGL</z:e> and SAA and +365 only to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CGL</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>In our study, the persistence of host cells in these proportions did not imply an unfavorable prognosis </plain></SENT>
<SENT sid="6" pm="."><plain>On the contrary, some patients with myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (5/15 33%) and SAA (4/21, 19%) showed high proportions of host cells in one or more periods analyzed </plain></SENT>
<SENT sid="7" pm="."><plain>If compared to the first group, these patients had, in general, a poor clinical evolution, with rejections, relapses, and <z:hpo ids='HP_0011420'>deaths</z:hpo> in greater numbers </plain></SENT>
<SENT sid="8" pm="."><plain>These results show the important contribution of cytogenetic analysis in the follow-up of patients submitted to BMT </plain></SENT>
</text></document>